A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
Reuven Or,Aliza Ackerstein,Arnon Nagler,Avraham Amar,Elizabeth Naparstek,G. Varadi,Joseph Kapelushnik,Simcha Samuel,Thea Pugatsch,Chaim Brautbar,Shimon Slavin +10 more
TL;DR: Cell-mediated immunotherapy at the stage of minimal residual disease in lymphoma patients to help effect a GVL-like reaction by adoptive transfer of immunocompetent human leukocyte antigen-matched donor peripheral blood lymphocytes (PBL).
Journal ArticleDOI
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
Arnon Nagler,Frédéric Baron,Myriam Labopin,Emmanuel Polge,Jordi Esteve,Ali Bazarbachi,Eolia Brissot,Eolia Brissot,Gesine Bug,Fabio Ciceri,Sebastian Giebel,Maria H. Gilleece,Norbert-Claude Gorin,Francesco Lanza,Zinaida Peric,Annalisa Ruggeri,Jaime Sanz,Bipin N. Savani,Christoph Schmid,Roni Shouval,Roni Shouval,Alexandros Spyridonidis,Jurjen Versluis,Mohamad Mohty +23 more
TL;DR: This survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD is the first step in the aim to include MRD status as a routine registry capture parameter in acute leukemia.
Journal ArticleDOI
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression
Jehonathan H. Pinthus,Yuval Sheffer,Arnon Nagler,Eduard Fridman,Yoram Mor,Olga Genina,Mark Pines +6 more
TL;DR: Halofuginone is a potent inhibitor of WT progression and may decrease the treatment burden when combined with chemotherapy, according to its unique mode of action.
Journal ArticleDOI
Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation.
Joseph Kapelushnik,Reuven Or,Dvora Filon,Arnon Nagler,G. Cividalli,Memet Aker,Ella Naparstek,S. Slavin,Ariella Oppenheim +8 more
TL;DR: The detection of beta-globin gene point mutation, as used here, is a highly specific and sensitive marker for engraftment and MC in patients with thalassemia and the high incidence of MC found in patients may be a consequence of the pre-BMT T-cell depletion.
Journal ArticleDOI
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.
Francine M. Foss,Steven M. Horwitz,Monica Civallero,Monica Bellei,Luigi Marcheselli,Won Seog Kim,Maria Elena Cabrera,Ivan Dlouhy,Arnon Nagler,Ranjana H. Advani,Emanuela Anna Pesce,Young Hyeh Ko,Silvia Montoto,Carlos S. Chiattone,Alison J. Moskowitz,Michele Spina,Marina Cesaretti,Irene Biasoli,Massimo Federico +18 more
TL;DR: While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%‐40% and were suboptimal for all groups, highlighting the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials.